ReNerve

ReNerve FCF Conversion

FCF Conversion Rate (FCF/EBITDA) of ReNerve (RNV.AX) as of Oct 18, 2026.

FCF Conversion

0.00

Last updated:

FCF Conversion Rate (FCF/EBITDA) of ReNerve is 2026 0.00 . FCF Conversion Rate (FCF/EBITDA) of ReNerve was 2025 101.08 % . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ReNerve Stock analysis

What does ReNerve do? ReNerve Ltd is an Australian company operating in the Health Care sector. It develops medical devices for peripheral nerve repair and replacement, focusing on tissue-based products that accelerate regeneration and prevent scarring. The company's products include NervAlign Nerve Cuff, designed to protect repaired nerves during surgery, and NervAlign Nerve Graft, which allows nerve repair without harvesting the sural nerve. NervAlign Bionic Nerve is under development, combining polymer technology to stimulate nerve injury sites. The company's IPO occurred on November 26, 2024. Its website is https://renerve.com.au/ ReNerve is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReNerve stock

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) ReNerve since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s ReNerve with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ReNerve

All Key Metrics — ReNerve